Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
20 déc. 2023 10h08 HE
|
Vivos Inc.
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy...
Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
24 janv. 2022 09h30 HE
|
Vivos Inc.
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®
23 nov. 2021 09h30 HE
|
Vivos Inc.
This replaces and corrects the press release from November 22. Johns Hopkins (VCTN) Veterinary Clinical Trials Network is our teaming partner not the Center for Image Guided Animal Therapy (CIGAT). ...
Vivos Inc Signs a MOU for a New Regional Clinic in NY for IsoPet Therapy
18 oct. 2021 09h30 HE
|
Vivos Inc.
Richland WA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East...
Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics
22 sept. 2021 09h30 HE
|
Vivos Inc.
Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training...
Vivos Inc Initiates Isopet® Therapy in Horses
24 juin 2021 09h30 HE
|
Vivos Inc.
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University...
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
09 déc. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...
Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors
03 sept. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to...
Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy
26 août 2020 09h30 HE
|
Vivos Inc.
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating...
Vivos Inc Achieves Important Radiogel™ Development Milestones
24 juin 2020 07h30 HE
|
Vivos Inc.
Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel™ for human therapy. Animal testing at the...